Nuvectis Pharma, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2024 Annual Meeting of Stockholders held on June 13, 2024. Nuvectis Pharma, Inc. (NVCT) is an emerging growth company incorporated in Delaware and listed on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Stockholders representing 12,227,134 shares (66.55% of outstanding shares) were present, constituting a quorum. All proposals were approved.
- Proposal 1 (Election of Class II Directors):
- Kenneth Hoberman: 8,026,155 votes For; 809,797 votes Against; 2,637 Abstentions; 3,388,545 Broker Non-Votes.
- Matthew Kaplan: 8,502,724 votes For; 333,228 votes Against; 2,637 Abstentions; 3,388,545 Broker Non-Votes.
- Proposal 2 (Ratification of Auditors): Ratification of Kesselman & Kesselman as independent registered public accounting firm for the fiscal year ending December 31, 2024.
- Results: 12,055,252 votes For; 31,882 votes Against; 140,000 Abstentions; 0 Broker Non-Votes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. Detailed descriptions of the proposals are referenced in the definitive proxy statement on Schedule 14A filed on April 29, 2024.
Key Facts for Investor Verification
- Verify the total number of shares outstanding (18,370,758) as of the record date of April 15, 2024.
- Confirm the tenure of the newly elected Class II directors (until the 2027 annual meeting).
- Review the Schedule 14A proxy statement for detailed biographies of directors and the rationale for auditor selection.
- Note the significant number of broker non-votes (3,388,545) on the director election proposals.